Direct‐to‐consumer advertising and the advancement of the quadruple aim: A narrative review

Khokhar, Bilal; Weathers, Shannon; Mattingly, Jill

doi:10.1002/jac5.1599

Cited by 1 publication

(7 citation statements)

References 67 publications

(174 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Direct-to-consumer advertising may increase patient requests for advertised products and the likelihood of their prescription by clinicians . Allocating a greater share of promotional spending to consumer advertising (vs promotions that target clinicians) may therefore reflect a strategy to drive patient demand for drugs that clinicians might be less likely to prescribe because either there are several similarly effective alternative treatments available or there is a more effective alternative available.…”

Section: Discussionmentioning

confidence: 99%

“…Direct-to-consumer advertising is associated with increased patient requests and increased clinician prescriptions for advertised products . This advertising strategy may also influence the relationship between patients and clinicians.…”

Section: Introductionmentioning

confidence: 99%

“…Increased patient requests for advertised products may present an opportunity for an informed discussion of treatment alternatives. Increased requests can also create additional burden for clinicians or lead to distrust and a worsened relationship between clinician and patient, especially when patient requests are not granted …”

Section: Introductionmentioning

confidence: 99%

“…T he US and New Zealand are the only countries that allow direct-to-consumer advertising for prescription drugs. 1,2 From 1997 to 2016, spending on advertisements for prescription drugs directed to consumers in the US grew from $1.3 billion to $6 billion, with the greatest increases observed among drugs to treat diabetes and endocrine conditions. 3 Direct-to-consumer advertising is associated with increased patient requests and increased clinician prescriptions for advertised products.…”

mentioning

confidence: 99%

“…3 Direct-to-consumer advertising is associated with increased patient requests and increased clinician prescriptions for advertised products. 1,4 This advertising strategy may also influence the relationship between patients and clinicians. Increased patient requests for advertised products may present an opportunity for an informed discussion of treatment alternatives.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Association Between Drug Characteristics and Manufacturer Spending on Direct-to-Consumer Advertising

DiStefano

Markell

Doherty

et al. 2023

JAMA

View full text Add to dashboard Cite

ImportanceSome drugs are heavily marketed through direct-to-consumer advertising.ObjectiveTo identify drug characteristics associated with a greater share of promotional spending on advertising directly to consumers.Design, Setting, and ParticipantsExploratory cross-sectional analysis of drug characteristics and promotional spending for the 150 top-selling branded prescription drugs in the US in 2020 as identified from IQVIA National Sales Perspectives data. Promotional spending data were provided by IQVIA ChannelDynamics.ExposuresDrug characteristics (total 2020 sales; total 2020 promotional spending; clinical benefit ratings; number of indications, off-label use; molecule type; nature of condition treated; administration type; generic availability; US Food and Drug Administration [FDA] approval year, World Health Organization anatomical therapeutic chemical classification; Medicare annual mean spending per beneficiary; percent sales attributable to the drug; market size; market competitiveness) assessed from health technology assessment agencies (France’s Haute Autorité de Santé and Canada’s Patented Medicine Prices Review Board) and drug data sources (Drugs@FDA, the FDA Purple Book, Lexicomp, Merative Marketscan Research Databases, and Medicare Spending by Drug data).Main Outcomes and MeasuresProportion of total promotional spending allocated to direct-to-consumer-advertising for each drug.ResultsThe 2020 median proportion of promotional spending allocated to direct-to-consumer advertising was 13.5% (IQR, 1.96%-36.6%); median promotional spending, $20.9 million (IQR, $2.72-$131 million); and median total sales, $1.51 billion (IQR, $0.97-$2.26 billion). Of the 150 best-selling drugs, 16 were missing data and key covariates; therefore, the primary study sample comprised 134 drugs. After adjustment for multiple drug characteristics, the mean proportion of total promotional spending allocated to direct-to-consumer advertising for the remaining 134 drugs was an absolute 14.3% (95% CI, 1.43%-27.2%; P = .03) higher for those with low added clinical benefit than for those with high added clinical benefit and an absolute 1.5% (95% CI, 0.44%-2.56%; P = .005) higher for each 10% increase in total sales.Conclusions and RelevanceAmong top-selling US drugs in 2020, a rating of lower added benefit and higher total drug sales were associated with a higher proportion of manufacturer total promotional spending allocated to direct-to-consumer advertising. Further research is needed to understand the implications of these findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations